PMID- 6869280
OWN - NLM
STAT- MEDLINE
DCOM- 19830826
LR  - 20190622
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 52
IP  - 3
DP  - 1983 Aug
TI  - Noncardiovascular findings associated with heart disease in the idiopathic 
      hypereosinophilic syndrome.
PG  - 321-4
AB  - Heart disease characterized by endomyocardial fibrosis is one of the major causes 
      of morbidity and mortality in the idiopathic hypereosinophilic syndrome. From our 
      series of 50 patients with idiopathic hypereosinophilia, we defined the 
      noncardiovascular characteristics that distinguish patients at risk of developing 
      endomyocardial fibrosis from those who remain free of heart disease. These groups 
      did not differ with respect to the extent of eosinophilia or the duration of 
      disease. Patients with clinically overt heart disease were more likely (p less 
      than 0.05) to be male and HLA-Bw44 positive and have splenomegaly, 
      thrombocytopenia, elevated serum levels of vitamin B12, and hypogranular or 
      vacuolated eosinophils and abnormal early myeloid precursors in the peripheral 
      blood. These idiopathic hypereosinophilic patients with heart disease were also 
      more likely to have fibrosis and decreased megakaryocytes in the bone marrow. In 
      contrast, those who remained free of heart disease tended to be female and have 
      angioedema, hypergammaglobulinemia, elevated serum levels of immunoglobulin E 
      (IgE), and circulating immune complexes. Therefore, in the idiopathic 
      hypereosinophilic syndrome, male patients with a myeloproliferative type disorder 
      and the HLA-Bw44 haplotype were at a much increased risk for the development of 
      endomyocardial fibrosis. However, those patients with a hypersensitivity-like 
      illness and angioedema who were female did not develop heart disease. 
      Appreciation of this relative degree of risk for the major complication of the 
      idiopathic hypereosinophilic syndrome should prove useful in the early 
      identification and appropriate treatment of patients in whom endomyocardial 
      fibrosis might develop.
FAU - Harley, J B
AU  - Harley JB
FAU - Fauci, A S
AU  - Fauci AS
FAU - Gralnick, H R
AU  - Gralnick HR
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
SB  - IM
MH  - Adult
MH  - Endomyocardial Fibrosis/blood/complications/*diagnosis
MH  - Eosinophilia/blood/*complications
MH  - Heart Diseases/blood/complications/*diagnosis
MH  - Humans
EDAT- 1983/08/01 00:00
MHDA- 1983/08/01 00:01
CRDT- 1983/08/01 00:00
PHST- 1983/08/01 00:00 [pubmed]
PHST- 1983/08/01 00:01 [medline]
PHST- 1983/08/01 00:00 [entrez]
AID - 0002-9149(83)90131-5 [pii]
AID - 10.1016/0002-9149(83)90131-5 [doi]
PST - ppublish
SO  - Am J Cardiol. 1983 Aug;52(3):321-4. doi: 10.1016/0002-9149(83)90131-5.